The 50 most recent market catalysts affecting $ABBV, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 16, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Adjusts Price Target on AbbVie to $335
Barclays, a prominent financial institution, has revised its price target for AbbVie Inc. upwards from $325 to $335. This change reflects an updated, more favorable outlook from th…
Nov 11, 2026
Corporate Catalyst
Bullish
Impact 55
Berenberg Lifts Price Target on AbbVie to $305 From $275
Berenberg, an investment firm, raised its price target for AbbVie (ABBV) from $275 to $305 and maintained its 'Buy' rating. This action signals increased confidence from the analys…
Nov 9, 2026
Corporate Catalyst
Bullish
Impact 55
Allergan Aesthetics Announces Results from Phase 4 Studies on Aesthetic Treatments for GLP-1 Patients
Allergan Aesthetics, a key subsidiary of AbbVie, announced positive results from two Phase 4 clinical studies. These studies evaluated the effectiveness of aesthetic treatments in …
Nov 6, 2026
Corporate Catalyst
Bullish
Impact 55
Argus Research Adjusts Price Target on AbbVie
Argus Research has raised its price target for AbbVie (ABBV) to $320 from $270, signaling increased confidence in the biopharmaceutical company's prospects. This adjustment follows…
Nov 4, 2026
Corporate Catalyst
Bullish
Impact 75
AbbVie Enters Global License Agreement with Nxera Pharma for IBD Drug Candidate
AbbVie has secured an exclusive global license for NXE0033744, a novel IBD drug candidate from Nxera Pharma. This transaction is significant as it provides AbbVie with a new potent…
Nov 3, 2026
Corporate Catalyst
Bullish
Impact 55
BNP Paribas Adjusts Price Target on AbbVie to $269
BNP Paribas has raised its price target on AbbVie Inc. to $269 from $247, indicating a more favorable valuation outlook for the biopharmaceutical company. This matters because anal…
Nov 2, 2026
Corporate Catalyst
Bullish
Impact 65
AbbVie Enters Global License Agreement with Brise Pharmaceuticals for Migraine Therapies
AbbVie has secured a global license agreement with Brise Pharmaceuticals for two preclinical migraine programs. This collaboration is significant as it allows AbbVie to bolster its…
Nov 2, 2026
Corporate Catalyst
Neutral
Impact 55
Wells Fargo, RBC Capital, Canaccord Genuity, and Cantor Fitzgerald Update Price Targets for AbbVie
On November 2, 2026, several prominent investment firms, including Wells Fargo, RBC Capital, Canaccord Genuity, and Cantor Fitzgerald, increased their price targets for AbbVie. Thi…
Nov 2, 2026
Corporate Catalyst
Neutral
Impact 65
Analyst Price Target Adjustments for AbbVie
On November 2, 2026, several prominent financial institutions, including Canaccord Genuity, RBC Capital, Cantor Fitzgerald, and Guggenheim, raised their price targets for AbbVie. T…
Nov 2, 2026
Corporate Catalyst
Neutral
Impact 55
Analysts Adjust Price Targets for AbbVie
On November 2, 2026, RBC Capital Markets, Cantor Fitzgerald, and Guggenheim all raised their price targets for AbbVie. RBC increased its target to $330 from $280, Cantor to $325 fr…
Nov 2, 2026
Corporate Catalyst
Neutral
Impact 55
Guggenheim and Cantor Fitzgerald Adjust Price Targets on AbbVie
Guggenheim and Cantor Fitzgerald have both raised their price targets for AbbVie, with Guggenheim moving from $288 to $322 and Cantor Fitzgerald from $290 to $325. This indicates a…
Oct 30, 2026
Corporate Catalyst
Bullish
Impact 92
AbbVie Reports Third-Quarter 2026 Financial Results and Increases Dividend
AbbVie announced Q3 2026 results that surpassed analyst consensus for both net revenues ($17.404 billion) and adjusted diluted EPS ($3.82). This strong performance, driven by immun…
Oct 29, 2026
Corporate Catalyst
Bullish
Impact 65
AbbVie Announces Results from TEMPLE Study of Atogepant (QULIPTA®)
AbbVie reported that its drug, atogepant (QULIPTA®), demonstrated superior tolerability and efficacy against topiramate in a Phase 3b clinical trial for migraine prevention. This i…
Oct 27, 2026
Corporate Catalyst
Bullish
Impact 65
AbbVie Submits BLA for Etentamig to FDA for Multiple Myeloma
AbbVie announced the submission of a Biologics License Application (BLA) to the FDA for etentamig, targeting relapsed or refractory multiple myeloma. This is a crucial regulatory m…
Oct 23, 2026
Corporate Catalyst
Bullish
Impact 65
FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI for Crohn's Disease
AbbVie announced FDA approval for a subcutaneous induction regimen of SKYRIZI for Crohn's disease, enabling patients to start treatment at home with an on-body injector. This is a …
Oct 22, 2026
Corporate Catalyst
Bullish
Impact 75
AbbVie Announces Positive Phase 3 Results for Lutikizumab in Hidradenitis Suppurativa
AbbVie announced that its Phase 3 INTREPID clinical trial for lutikizumab in hidradenitis suppurativa met its primary endpoint, demonstrating significant improvements over placebo.…
Oct 22, 2026
Corporate Catalyst
Bullish
Impact 55
Goldman Sachs Adjusts Price Target on AbbVie
Goldman Sachs has raised its price target for AbbVie (ABBV) from $258 to $294, indicating a more favorable outlook on the biopharmaceutical company's valuation. This adjustment is …
Oct 22, 2026
Corporate Catalyst
Bullish
Impact 55
Health Canada Approves AbbVie's Skyrizi for Pediatric Plaque Psoriasis
AbbVie announced that Health Canada has approved its drug Skyrizi (risankizumab) for pediatric patients aged 6 to under 18 with moderate-to-severe plaque psoriasis. This approval i…
Oct 21, 2026
Corporate Catalyst
Neutral
Impact 65
Abbvie Signs ELAHERE Reimbursement LoI With The Pan-Canadian Pharmaceutical Alliance
AbbVie has reached a crucial milestone by signing a Letter of Intent with the Pan-Canadian Pharmaceutical Alliance (pCPA) for the reimbursement of ELAHERE, its innovative platinum-…
Oct 20, 2026
Corporate Catalyst
Bullish
Impact 75
AbbVie shares are trading higher after Health Canada approved SKYRIZI for pediatric plaque psoriasis patients and the company announced a multiyear partnership with the McLaren Mastercard Formula 1 Team.
AbbVie's shares are trading higher due to two distinct positive developments. The Health Canada approval of SKYRIZI for pediatric plaque psoriasis expands the drug's addressable ma…
Oct 19, 2026
Corporate Catalyst
Bullish
Impact 75
AbbVie’s Dual-Target Drug Shows Phase 2 Results for Hard-to-Treat Crohn’s Disease
AbbVie announced promising Phase 2a results for ABBV-466, a dual-targeting therapy for Crohn's disease, demonstrating superior endoscopic remission rates compared to monotherapies,…
Oct 19, 2026
Corporate Catalyst
Bullish
Impact 55
Reported Saturday, AbbVie Says Rinvoq Sustains Crohn’s Endoscopic Remission Of 47.1%-64.2% At Week 144 Through About Four Years, Skyrizi Sustains Ulcerative Colitis Endoscopic Remission Of 38.8%-53.5% At Week 96 At UEGW
AbbVie's 8-K filing details upcoming scientific presentations at the United European Gastroenterology Week (UEGW), focusing on long-term data for its key inflammatory bowel disease…
Oct 19, 2026
Corporate Catalyst
Bullish
Impact 65
Reported Sunday, AbbVie Plans ESMO 2026 Update Showing ABBV-706 Achieved 56% ORR And 12.4-Month Median OS In 2L+ Small Cell Lung Cancer, With 82% ORR In 2L-Only Patients
AbbVie filed an 8-K to announce its plans for ESMO 2026, where it will present new and updated data across seven oncology assets. This is significant because clinical trial data, e…
Oct 16, 2026
Corporate Catalyst
Neutral
Impact 65
Live On CNBC, Kevin Simpson Announces Bought AbbVie
Kevin Simpson's announcement of buying AbbVie (ABBV) on CNBC is a moderate corporate catalyst. While not a fundamental change in the company's operations, a well-known investor's p…
Oct 13, 2026
Corporate Catalyst
Bullish
Impact 65
AbbVie Announces Data From Its Phase 3 AFFIRM Study Of SKYRIZI Demonstrates 35.8% Of Patients With Crohn's Disease Achieved Endoscopic Remission After Treatment
AbbVie released new, detailed efficacy results from its Phase 3 AFFIRM study for SKYRIZI in Crohn's disease, presented at a scientific meeting. The key finding is that 35.8% of pat…
Oct 12, 2026
Market Technicals
Neutral
Impact 55
CNBC Halftime Report Final Trades: AbbVie, DocuSign, Netflix
The 'CNBC Halftime Report Final Trades' segment is a popular feature that often leads to increased trading activity and short-term price fluctuations for the highlighted stocks. Wh…
Oct 12, 2026
Corporate Catalyst
Bullish
Impact 65
Reported Sunday, AbbVie’s SKYRIZI Shows Sustained Endoscopic Outcomes Through 144 Weeks In Crohn’s And 74.5% Fistula Resolution At Five Years, While RINVOQ Real-World Data Show Remission In Advanced Crohn’s
AbbVie's 8-K filing highlights new Phase 3 and real-world data for SKYRIZI and RINVOQ, respectively, showing sustained efficacy in Crohn's disease patients. This is significant as …
Oct 9, 2026
Corporate Catalyst
Bullish
Impact 55
UBS Maintains Neutral on AbbVie, Raises Price Target to $275
UBS analyst Michael Yee maintained a 'Neutral' rating on AbbVie, but increased the price target from $260 to $275. This action suggests that while UBS doesn't see a compelling reas…
Oct 8, 2026
Corporate Catalyst
Bullish
Impact 55
JP Morgan Maintains Overweight on AbbVie, Raises Price Target to $300
JP Morgan analyst Chris Schott has maintained an 'Overweight' rating on AbbVie and raised the price target from $285 to $300. This action signals continued confidence in AbbVie's f…
Oct 8, 2026
Corporate Catalyst
Bullish
Impact 55
Cantor Fitzgerald Maintains Overweight on AbbVie, Raises Price Target to $290
Cantor Fitzgerald analyst Carter Gould has maintained an 'Overweight' rating on AbbVie and slightly increased the price target from $285 to $290. This action signals continued conf…
Oct 7, 2026
Corporate Catalyst
Bullish
Impact 55
Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $310
Morgan Stanley analyst Terence Flynn maintained an 'Overweight' rating on AbbVie and raised the price target from $296 to $310. This action signals a positive outlook from a promin…
Oct 7, 2026
Corporate Catalyst
Bullish
Impact 75
AbbVie Receives Two New FDA's Breakthrough Therapy Designations For Telisotuzumab Adizutecan In Colorectal Cancer, Non-Small Cell Lung Cancer
AbbVie announced that its experimental drug, telisotuzumab adizutecan, received two Breakthrough Therapy Designations (BTDs) from the FDA for colorectal cancer and non-small cell l…
Oct 6, 2026
Corporate Catalyst
Bullish
Impact 55
Scotiabank Maintains Sector Outperform on AbbVie, Raises Price Target to $320
Scotiabank analyst Louise Chen maintained a 'Sector Outperform' rating on AbbVie and raised the price target from $280 to $320. This action signals continued confidence in AbbVie's…
Oct 5, 2026
Corporate Catalyst
Bearish
Impact 85
AbbVie Lowers FY2026 Adjusted EPS Guidance To $13.76-$13.96/Share, Q3 To $3.73-$3.77/Share, On $216M Acquired R&D And Milestone Expense
This headline represents a significant corporate catalyst for AbbVie. The downward revision of both short-term (Q3) and long-term (FY2026) adjusted EPS guidance indicates a materia…
Oct 1, 2026
Corporate Catalyst
Bullish
Impact 65
AbbVie Presents Data From Its Current Phase 3 Viti-Up-1, Viti-Up-2 Trials Of RINVOQ At 2026 European Academy Of Dermatology And Venereology Congress
AbbVie presented positive late-breaking Phase 3 data for its drug RINVOQ in treating non-segmental vitiligo. The filing highlights continued repigmentation through 76 weeks and imp…
Sep 30, 2026
Corporate Catalyst
Bullish
Impact 75
AbbVie Reveals Positive Data for Eczema and Weight Loss Candidates
AbbVie has reported encouraging clinical trial results for two significant pipeline assets. Zumilokibart, an eczema treatment, showed statistically significant improvements in skin…
Sep 30, 2026
Corporate Catalyst
Bullish
Impact 75
AbbVie Says All Three Zumilokibart Dose Regimens Met Primary Endpoint With Significantly Greater EASI-75 Response Vs Placebo At Week 16 In Phase 2 APEX Part B Atopic Dermatitis Study
AbbVie reported that its investigational drug, zumilokibart, for atopic dermatitis, successfully met its primary endpoint in a Phase 2 study. All three dose regimens showed signifi…
Sep 29, 2026
Corporate Catalyst
Bullish
Impact 55
AbbVie And Valkai Collaborate To Accelerate Pace Of Scientific Innovation's Reach To Patients
AbbVie announced a new partnership with Valkai to enhance its artificial intelligence infrastructure, specifically targeting improvements in clinical research efficiency. This coll…
Sep 28, 2026
Corporate Catalyst
Neutral
Impact 75
AbbVie’s New Parkinson’s Pill Could Become a Billion-Dollar Drug, Analyst Says
AbbVie's new Parkinson's drug, Juvmo, received FDA approval, a major milestone for the company. This approval is significant as it's the first dopaminergic breakthrough for Parkins…
Sep 28, 2026
Corporate Catalyst
Bullish
Impact 75
AbbVie Receives FDA's Approval For JUVMO To Treat Adults with Parkinson's Disease
AbbVie announced that the FDA has approved JUVMO (tavapadon) for the treatment of adults with Parkinson's disease. This is a significant development as JUVMO is the first and only …
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 55
AbbVie Receives European Commission Approval Of RINVOQ For Children With Active Polyarticular Juvenile Idiopathic Arthritis Aged Two And Older
AbbVie's RINVOQ has received European Commission approval for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in children aged two and older. This is a p…
Sep 21, 2026
Corporate Catalyst
Bullish
Impact 65
AbbVie Enters Multi-Year Collaboration With Iambic To Accelerate Discovery And Development Of Small Molecule Therapies Across Immunology, Neuroscience And Oncology; Iambic To Receive Upfront Payment And Is Eligible For Milestone Payments And Tiered Royalties
AbbVie has announced a strategic collaboration with Iambic, an AI-driven drug discovery company, to utilize Iambic's 'molecular superintelligence platform' for identifying and deve…
Sep 18, 2026
Corporate Catalyst
Bullish
Impact 75
AbbVie Says Real-World Studies Show VRAYLAR Improved Depressive Symptoms In Bipolar I Depression, Adjunctive Major Depressive Disorder At Psych Congress 2026
The positive real-world study results for VRAYLAR are a significant corporate catalyst for AbbVie. This data, presented at a major medical conference, validates the drug's efficacy…
Sep 15, 2026
Corporate Catalyst
Neutral
Impact 65
AbbVie Exec Says Plans To Start Enrolling Apogee's Zumilokibart This Year, Targets Launch In Early 2030; Says Will Present Late-stage Data For Blood Cancer Drug Etentamig At International Myeloma Society Meeting Later In September
AbbVie's executive provided an update on two key pipeline assets: Zumilokibart and Etentamig. The plan to start enrolling patients for Zumilokibart this year, with a target launch …
Sep 11, 2026
Corporate Catalyst
Bullish
Impact 75
What's Going On With AbbVie Stock Friday?
AbbVie's announcement of positive Phase 3 trial results for atogepant in menstrual migraine is a significant clinical win, expanding its CGRP neuroscience franchise into an area wi…
Sep 10, 2026
Corporate Catalyst
Bullish
Impact 75
AbbVie Drug Shows Significant Reductions in Menstrual Migraine Days
AbbVie released positive topline results from its Phase 3 LUNA clinical trial for atogepant, an oral CGRP receptor antagonist, as a preventive medication for menstrual migraines. T…
Sep 10, 2026
Corporate Catalyst
Bullish
Impact 55
HSBC Maintains Buy on AbbVie, Raises Price Target to $315
HSBC analyst Rajesh Kumar maintained a 'Buy' rating on AbbVie and raised the price target from $300 to $315. This action signals increased confidence from a prominent financial ins…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.